|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT01212549 |
|
Date of registration:
|
29/09/2010 |
|
Primary sponsor: |
|
|
Public title:
|
Comparison of Two Schemes of Cryosurgery and Imiquimod Combination Treatment for Basal Cell Carcinoma
IMCXvsCIMT |
|
Scientific title:
|
Open Label, Randomized Comparison of Two Schemes of Cryosurgery and Imiquimod Combination Treatment for Basal Cell Carcinoma of the Skin |
|
Date of first enrolment:
|
February 2009 |
|
Target sample size:
|
14 |
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT01212549 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
|
|
|
Countries of recruitment
|
|
Greece
| | | | | | | |
|
Contacts
|
|
Name:
|
Ioannis D Bassukas, Professor |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Medical School, University of Ioannina |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Biopsy proven basal cell carcinoma of the skin
- Size <5cm
- Number of tumors <5 cm
- Distance from eyelids, mouth 0,5cm
Exclusion Criteria:
- Size >5cm
- Number of tumors > or =5
- Distance from eyelids or mouth < or =0.5cm
Age minimum:
18 Years
Age maximum:
80 Years
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Basal Cell Carcinoma
|
|
Intervention(s)
|
|
Procedure: Cryoimmunotherapy
|
|
Procedure: Immunocryosurgery
|
|
Primary Outcome(s)
|
|
Comparison of the efficacy of immunocryosurgery and cryoimmunotherapy
[Time Frame: 1 month]
|
|
Secondary ID(s)
|
|
524270910
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|